The aging of the HIV-positive population is quietly reshaping one of the most complex intersections in American medicine: the convergence of long-term antiretroviral management, accelerated biological aging, and a Medicare system not originally designed to carry this burden. Understanding the scale of this shift matters for clinicians, health system planners, and anyone tracking the long-term economics of chronic disease management.
Using the CHARMED simulation model — a validated framework incorporating cardiovascular, neurological, and mental health comorbidity trajectories — investigators projected that the number of people with HIV (PWH) enrolled in Medicare and actively in care will rise from approximately 121,890 at the end of 2026 to 193,560 by the end of 2035, nearly a 60% increase. The modeled cohort of 111,600 at baseline had a mean age of 70.9 years, with 77% male, reflecting the demographic profile of those who survived the early epidemic era. Growth was projected across all age strata, with notable expansion in the 75-and-older subgroups — populations carrying the heaviest comorbidity burden. Costs were projected using 2023 traditional Medicare claims data, adjusted for health care inflation and Medicare Advantage enrollment patterns.
This analysis arrives at a critical moment in HIV medicine. Antiretroviral therapy has transformed HIV into a manageable chronic condition, but survival gains have come with a distinct clinical penalty: PWH age biologically faster than HIV-negative peers, accumulating cardiovascular disease, neurocognitive decline, renal dysfunction, and bone fragility at higher rates and earlier ages. This means per-beneficiary costs are not simply additive — they compound with polypharmacy, hospitalization risk, and complex care coordination needs. The study's simulation-based design is a strength, but projections remain sensitive to assumptions about treatment adherence, new entrants to the 65+ cohort, and antiretroviral cost trajectories, particularly as long-acting injectable regimens enter broader use. Taken together, this is an incrementally important but practically urgent forecast — less a scientific surprise than a demographic inevitability that health systems must plan for now.
